Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisSteven M. Opal, for the ACCESS Study Group, Thierry Dugernier et al.|JAMA|2013Cited by 797
Influenza virus-related critical illness: pathophysiology and epidemiologyAndré C. Kalil, Paul G. Thomas|Critical Care|2019Cited by 509
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*Jean‐Louis Vincent, Gordon R. Bernard, Derek C. Angus et al.|Critical Care Medicine|2003Cited by 302
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3Ted R. Mikuls, Kenneth G. Saag, Sindhu R. Johnson et al.|Arthritis & Rheumatology|2020Cited by 242
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 1Ted R. Mikuls, Kenneth G. Saag, Sindhu R. Johnson et al.|Arthritis & Rheumatology|2020Cited by 186